Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Soleno Therapeutics (SLNO) Shares Outstanding (Weighted Average) (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed Shares Outstanding (Weighted Average) for 9 consecutive years, with $50.8 million as the latest value for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) changed N/A year-over-year to $50.8 million; the TTM value through Dec 2025 reached $50.8 million, changed N/A, while the annual FY2025 figure was $50.8 million, N/A changed from the prior year.
  • Shares Outstanding (Weighted Average) hit $50.8 million in Q4 2025 for Soleno Therapeutics, up from $50.0 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $50.8 million in Q4 2025 and bottomed at $46.2 million in Q1 2025.